Mechanisms and Applications of Metformin in Human Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (30 September 2023) | Viewed by 1453
Special Issue Editors
2. Metabolism & Cancer Group, Girona Biomedical Research Institute (IDIBGI), 17190 Girona, Spain
Interests: cancer; metabolism; metformin; aging; drug development
Special Issues, Collections and Topics in MDPI journals
2. Catalan Institute of Oncology (ICO)-Girona Biomedical Research Institute (IDIBGI), 17190 Girona, Spain
Interests: cancer; metabolism; metformin; aging; drug development
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
An ever-growing accumulation of epidemiological, pre-clinical, and clinical data is stimulating the interest in repositioning or re-tasking the biguanide metformin to treat a wide variety of diseases outside the scope of its original medical indication, type 2 diabetes (T2D). Indeed, clinical trials, such as MILES (Metformin in Longevity Study) and TAME (Targeting Aging with Metformin), have been designed to determine if metformin can directly target the aging machinery to extend healthspan. While the jack-of-all-trades behavior of metformin in human health is certainly indisputable, it remains unclear as to whether all the putative health-promoting effects of metformin are secondary to its insulin-sensitizing and glucose-lowering effects or result from other direct or indirect actions on the biological causes or hallmarks of aging and health. Moreover, there is an urgent need to clarify whether the pharmacological targets identified with supra-therapeutic concentrations of metformin may be of clinical relevance at the mechanistic level.
To encompass the remarkable breadth of ongoing investigation on metformin and aging-related diseases, research articles, short communications, review articles, as well as clinical studies covering a wide range of topics related to the therapeutic application of metformin (or metformin derivatives) in chronic diseases, hereditary genetic disorders, and rare diseases, in addition to T2D, such as chronic respiratory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, as well as viral infections, including SARS-CoV-2/COVID-19, will be welcomed in this Special Issue in Pharmaceuticals. We aim to include manuscripts, including but not limited to, metformin-centered molecular mechanisms, signaling pathways, metabolism, pre-clinical models, drug formulations, analogues, drug combinations, immune response, and clinical trials. With the manuscript compendium, we will generate a molecular–clinical map of the mechanisms by which metformin not only mitigates the drivers of aging diseases but also its ability to boost (or to prevent pathogenic disruption of) the organizational and dynamical hallmarks that maintain the physiological state in human health.
Dr. Elisabet Cuyàs
Dr. Javier A. Menendez
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metformin
- metformin derivatives
- molecular mechanisms of action
- cellular mechanisms of action
- metabolism and bioavailability
- drug development
- analogs
- pre-clinical studies
- cancer
- hereditary cancer
- ataxia-telangiectasia (A-T)
- BRCA1
- polymorphisms
- genetic risk
- rare diseases
- epigenetic
